Business Wire

PA-BOOMI

13.6.2024 10:01:37 CEST | Business Wire | Press release

Share
Boomi Research Reveals Composability Essential to Overcome Legacy System Challenges in Enterprises

Boomi™, the intelligent integration and automation leader, today announced findings of a new global study.1 The IDC InfoBrief, sponsored by IFS and Boomi, reveals that aging, monolithic systems, and a lack of technological understanding at the executive level limit organizational agility and responsiveness to disruptions. The research also identified that having a composable strategy is key for organizations to overcome these challenges.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613200694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Research Reveals Composability Essential to Overcome Legacy System Challenges in Enterprises (Graphic: Business Wire)

The study polled over 1,000 C-level respondents across 12 countries in Europe, North America, Middle East, Africa, and Asia Pacific. It found that legacy technology platforms and unfamiliarity with the essential role Application Programming Interfaces (APIs) and composability play in unlocking business data are combining to hamper insights and transformation.

The widely acknowledged risks of not transitioning to composable applications have become even more pressing against the backdrop of current domestic and international upheavals. Recent developments such as Brexit, world issues, and the escalating cost-of-living crises have highlighted the deficiencies of outdated technologies.

While most businesses believe they have withstood the last three years of disruption, leaders report that working capital and inventory imbalances (56%), volatile demand (53%), and unpredictable supply chains (48%) had been their biggest challenges. Respondents also pointed to legacy applications (60%), lack of integration (48%), and inflexible/monolithic applications (43%) as hindering efforts to overcome these challenges - impacting the efficiency with which they can mitigate risks.

The research also revealed that the consequences of outdated technology platforms are being felt by businesses, with reports of limited visibility into operational processes (24%) and poor internal collaboration (18%). These findings suggest that companies struggle to use their data in long-term planning, hampering business agility and the ability to respond to future disruptions effectively.

With more than two-fifths (41%) of organizations lacking a composable strategy, the risk of stagnation and mounting technical debt is glaring. While the value of a composable architecture is well understood by over 70% of the C-suite respondents with business and functional responsibilities, the Board level professionals lag in their understanding - only 19% are clear on the value composability creates. This gulf between senior level executives points to a need for education and clearer business cases that highlight composability’s short, medium, and long-term value.

“This research sends a clear message to executives: To remain competitive, increase agility, and drive productivity across their entire business, composability is key,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “Speed to realizing value requires a strong data foundation and a mature cloud strategy as prerequisites to the adoption of other advanced technologies.”

Encouragingly, 89% of respondents identified API-driven innovation as a key component of composability with over half (51%) pointing to seamless integration between process workflows, and 37% to the importance of single-platform solutions. As well as highlighting the essential role of APIs in creating adaptable and flexible business systems, these findings support the notion that the future of business applications is composable.

In terms of technology preferences, APIs lead the way with 82% of respondents emphasizing their significance, followed by Artificial Intelligence (45%) and Machine Learning (40%). The research indicated that supply chain (51%), procurement (47%), and customer service and support (40%) are the top areas organizations believe they would benefit from application composability.

Despite the recognized importance of composability, the challenges identified in the research highlight the need for broader organizational alignment and clarity in technological direction to fully leverage the advantages of a composable architecture, where APIs play a foundational role.

Nevertheless, the survey data does reveal a significant trend towards investing in composing workflows with multiple products using APIs. Twenty-two percent of respondents reported to be actively pursuing this approach, reflecting a strategic move towards leveraging APIs for integrating diverse systems and applications to drive efficiency and innovation, and eliminate waste.

Macosky concluded: “Inertia in moving to the cloud or formulating a clear composability strategy is likely to prevent businesses from unlocking the full value of AI and machine learning technology. The challenge for organizations now is to realize value pervasively. However, they must overcome considerable barriers, such as the lack of understanding of composability’s value at the executive level and inadequate progression within cloud journeys. It should therefore come as little surprise that the CIO and CTO are the primary champions for composability.”

Additional Resources

  • Download the IDC InfoBrief, sponsored by IFS and Boomi, a Global Study of Composability in Enterprise Software and Evolving Business Needs.
  • Watch this webinar that explores the findings of the study with guest speakers from IDC, Boomi, and IFS.

About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

____________________________
1 IDC InfoBrief, sponsored by IFS and Boomi, Global Study of Composability in Enterprise Software and Evolving Business Needs, doc #US51992524, April 2024. In December 2023, over 1,000 senior business decision makers across 12 countries were polled from the manufacturing, energy and utilities, aerospace and defense, construction and engineering, telecoms, and service industries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613200694/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye